Clinical trial NCT05121428: Patients' Attitudes Toward and Experiences With Buprenorphine Treatment
Official title: Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Opioid-use Disorder
Acceptability of Health Care
Opioid-Related Disorders
Keywords: Opioid Use Disorder
Substance Use Disorders
Buprenorphine
Suboxone
Cannabis
Cigarettes
E-Cigarettes
Benzodiazepines
Healthcare
COVID-19
Telemedicine
Office-Based Opioid Treatment
Facebook
Social Media
Nicotine
Recovery
Lead sponsor: Cambridge Health Alliance
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: National Center for Complementary and Integrative Health (NCCIH)
First posted: 2021-11-16
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The subject population consists of adults aged 18+ who live in Massachusetts and are currently prescribed buprenorphine by a healthcare provider to treat OUD. Those under the age of 18 will be screened out of the investigation during the consent process. In addition, because many of the survey questions used in this investigation are based on established survey instruments that were created in the English language and validated among English-speaking participants, we will limit the subject population or this study to English-speaking adults.

Brief summary: This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Detailed description: The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances.

Eligibility criteria: Inclusion Criteria:

* Participants must be 18 years of age or older.
* Participants report currently having a legal prescription for buprenorphine for opioid use disorder.
* Participants must have a past or present opioid use disorder.
* Participants must currently reside in the state of Massachusetts.
* Participants must be able to comprehend the English language.

Exclusion Criteria:

* Unable to complete an online survey.
* Unable to complete a verification step that ensures bots are not used to complete survey.
* Complete a survey with no variation suggesting they did not read the survey.

Primary outcomes:
measure: Patient's Experiences with Office-Based Opioid Treatment
timeFrame: Day 1
measure: Reasons for Abstaining from Opioids Questionnaire
timeFrame: Day 1
measure: Patients' Attitudes Toward the Use of Cannabis During Office-Based Opioid Treatment
timeFrame: Day 1
measure: Patients' Attitudes Toward the Use of Cigarettes/E-Cigarettes During Office-Based Opioid Treatment
timeFrame: Day 1
measure: Patients' Attitudes Toward and Experiences with the Use of Benzodiazepines during Office-Based Opioid Treatment
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: CHA Center for Mindfulness and Compassion
state: Massachusetts
Study officials:
affiliation: Cambridge Health Alliance
name: Zev Schuman-Olivier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cambridge Health Alliance
name: Joseph Rosansky
role: STUDY_DIRECTOR
References: